Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Alpharma to withdraw and resubmit NDA to the FDA for Embeda

April 25, 2008

New anxiolytic and antidepressant agents disclosed in recent patent literature

April 25, 2008

Sygnis receives E.U. orphan drug designation for AX-200 in ALS

April 25, 2008

FDA approves Vyvanse to treat adult ADHD

April 25, 2008

Novel agents for neurological disorders described in recent AstraZeneca and Merck Frosst patents

April 24, 2008

Dainippon Sumitomo Pharma launches Lonasen for schizophrenia

April 24, 2008

ARYx receives FDA clearance for phase I ATI-9242 trial

April 23, 2008

Amerge launched in Japan for migraine

April 23, 2008

Clinical pharmacokinetic profile of XP-13512 reported at the AAN meeting

April 23, 2008

Motor improvement with pardoprunox in patients with early-stage PD seen in phase II trial

April 23, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...